Literature DB >> 31423281

Diagnostic and prognostic factors for patients with primary pulmonary non-Hodgkin's lymphoma: A 16-year single-center retrospective study.

Jiang Qian1,2, Dong-Lan Luo3, Jin-E Zhang4, Wen-Yu Li5, Xing-Lin Gao1, Xiang-Feng Fang1, Hong An1, Jun-Liang Deng1, Qiong Li1, Jian Wu1.   

Abstract

Primary pulmonary non-Hodgkin's lymphoma (PP-NHL) is a rare entity with non-specific symptoms and radiographic findings, as well as a difficult preoperative diagnosis. A limited number of studies have described PP-NHL in Chinese patients. The goal of the present study was to improve early diagnosis by examining prognostic factors in patients with PP-NHL. Therefore, a total of 29 patients with PP-NHL were included in the study between January 2001 and June 2017, including 14 with aggressive-type and 15 with indolent-type lymphomas (10 male, 19 female; median age, 50.3 years; range, 19-87 years). Pulmonary nodules and masses (55.2%) were the most common radiographic features. The diagnostic yield was 80% (12/15) by endobronchial biopsy or transbronchial lung biopsy and 100% by computed tomography (CT)-guided percutaneous needle lung biopsy (11/11) or surgery (8/8). Elevated lactate dehydrogenase levels and systemic symptoms were observed considerably more often in patients with aggressive disease than in those with indolent disease. The 1-, 3- and 5-year overall survival (OS) rates were 42, 32, and 21%, respectively, for all patients, 72, 57 and 43%, respectively, for patients with indolent lymphomas, and 13, 6 and 0%, respectively, for patients with aggressive lymphomas. The median OS rate for all patients was 12.0 months; however, the OS rate for patients with aggressive lymphomas was significantly shorter compared with those with indolent lymphomas (7.1 months vs. 16.6 months; P=0.002). Aggressive vs. indolent lymphoma status was indicated to be an independent prognostic factor for poor 5-year OS rate (hazard ratio, 5.98; P=0.014). In conclusion, bronchoscopic and CT-guided percutaneous needle lung biopsies were the most useful and least invasive procedures for diagnosing PP-NHL. Furthermore, aggressive PP-NHL was highly associated with poor 5-year OS rate and a poor prognosis.

Entities:  

Keywords:  biopsy; pathology; primary pulmonary non-Hodgkin's lymphoma; prognostic factors; survival

Year:  2019        PMID: 31423281      PMCID: PMC6607040          DOI: 10.3892/ol.2019.10469

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Primary pulmonary non-Hodgkin's lymphoma.

Authors:  Jung Han Kim; Se-Hoon Lee; Jinny Park; Ho Young Kim; Soon Il Lee; Joon-Oh Park; Kihyun Kim; Won Seog Kim; Chul Won Jung; Young Suk Park; Young-Hyuck Im; Won Ki Kang; Mark H Lee; Keunchil Park; Joung Ho Han; Young Hyeh Ko
Journal:  Jpn J Clin Oncol       Date:  2004-09       Impact factor: 3.019

3.  Clinical characteristics and prognostic factors of pulmonary MALT lymphoma.

Authors:  R Borie; M Wislez; G Thabut; M Antoine; A Rabbat; L-J Couderc; I Monnet; H Nunes; F-X Blanc; H Mal; A Bergeron; D Dusser; D Israël-Biet; B Crestani; J Cadranel
Journal:  Eur Respir J       Date:  2009-06-18       Impact factor: 16.671

4.  Primary pulmonary lymphoma.

Authors:  Brian B Graham; Douglas J Mathisen; Eugene J Mark; Ronald W Takvorian
Journal:  Ann Thorac Surg       Date:  2005-10       Impact factor: 4.330

5.  Primary non-Hodgkin's lymphoma of the lung.

Authors:  P Ferraro; V F Trastek; H Adlakha; C Deschamps; M S Allen; P C Pairolero
Journal:  Ann Thorac Surg       Date:  2000-04       Impact factor: 4.330

6.  Role of surgery in the treatment of primary pulmonary B-cell lymphoma.

Authors:  Frederic Vanden Eynden; Elie Fadel; Marc de Perrot; Vincent de Montpreville; Sacha Mussot; Philippe Dartevelle
Journal:  Ann Thorac Surg       Date:  2007-01       Impact factor: 4.330

7.  Prognostic factors of Chinese patients with primary pulmonary non-Hodgkin's lymphoma: the single-institute experience in Taiwan.

Authors:  Yu-Hui Hu; Liang-Tsai Hsiao; Ching-Fen Yang; Tzeon-Jye Chiou; Jin-Hwang Liu; Jyh-Pyng Gau; Chueh-Chuan Yen; Teh-Ying Chou; Wen-Hu Hsu; Po-Min Chen; Cheng-Hwai Tzeng
Journal:  Ann Hematol       Date:  2009-01-13       Impact factor: 3.673

Review 8.  Primary pulmonary lymphoma.

Authors:  J Cadranel; M Wislez; M Antoine
Journal:  Eur Respir J       Date:  2002-09       Impact factor: 16.671

Review 9.  Anaplastic Large Cell Lymphoma.

Authors:  L Jeffrey Medeiros; Kojo S J Elenitoba-Johnson
Journal:  Am J Clin Pathol       Date:  2007-05       Impact factor: 2.493

10.  Primary pulmonary non-Hodgkin's lymphoma: a retrospective analysis of 29 cases in a Chinese population.

Authors:  Jiajia Huang; Tongyu Lin; Zhi-Ming Li; Ruihua Xu; Huiqiang Huang; Wenqi Jiang
Journal:  Am J Hematol       Date:  2010-07       Impact factor: 10.047

View more
  3 in total

Review 1.  Clinical Analysis of 50 Cases of Primary Pulmonary Lymphoma: A Retrospective Study and Literature Review.

Authors:  Mingbin Hu; Weiguo Gu; Shaoqing Chen; Jinhong Mei; Weijia Wang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

2.  Surgery and chemotherapy cannot improve the survival of patients with early-stage mucosa-associated lymphoid tissue derived primary pulmonary lymphoma.

Authors:  Huahang Lin; Ke Zhou; Zhiyu Peng; Linchuan Liang; Jie Cao; Jiandong Mei
Journal:  Front Oncol       Date:  2022-08-23       Impact factor: 5.738

3.  Rapidly progressing primary pulmonary lymphoma masquerading as lung infectious disease: A case report and review of the literature.

Authors:  Jin-Hong Jiang; Chun-Lai Zhang; Qin-Li Wu; Yong-Hua Liu; Xiao-Qiu Wang; Xiao-Li Wang; Bing-Mu Fang
Journal:  World J Clin Cases       Date:  2021-06-06       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.